
Innovation in Urothelial cancer

Dirigido a profesionales
Formato presencial y online



Inscríbete / sign up
AQUÍ / HERE

12 November 2026

16:00-18:30 (CET) · Hybrid format

Hospital Universitario HM Sanchinarro,
Auditorio Reina Sofía
C/ de Oña, 10, 28050
Madrid

Organiza:

fundaciónhm investigación

Director:

Dra. Elena Sevillano Fernández
M.D. PhD Unidad de Tumores Urológicos, Ginecológicos y piel
HM Hospitales

Coordinador

Dr. Jesús García-Donas
M.D PhD M.D. Unidad de Tumores Urológicos, Ginecológicos y piel

Patrocinan:

Pfizer · MERCK · astellas · natera · ROC CLINIC · AstraZeneca · Johnson&Johnson · Bristol Myers Squibb

Programa

Precision Bladder Cancer: ctDNA, ADCs and the Future of Organ Preservation"

Speakers:
Dr. Joaquim Bellmunt *Dr. Pablo Gajate*
Dr. Guillermo de Velasco *Dr. Alfonso Gómez de Liaño*
Dr. Félix Guerrero

Course Directors :
Dra. Elena Sevillano
Dr. Jesús García-Donas

16:00 – 16:10 | Welcome and Introduction.
From Radical Surgery to Molecular Personalization

- Why urothelial cancer is changing faster than ever
- The transition from standard algorithms to precision

SESSION I – NON–MUSCLE-INVASIVE DISEASE

16:10 – 16:40 | BCG-Unresponsive Disease in 2026: Are We Replacing Cystectomy?

- IO + BCG combinations
- TAR-200, CG0070, N-803 and novel intravesical platforms
- How should we redefine BCG failure?
- Who should still undergo early cystectomy?
- Biomarkers for NMIBC decision-making

SESSION II – SESSION II — MIBC & BLADDER-SPARING

16:40 – 17:25 | The New Era of Bladder Preservation

- ctDNA-guided strategies
- Defining true clinical complete response
- Response-adapted treatment approaches
- Can we safely omit cystectomy?
- Is ctDNA clearance a surrogate endpoint?
- Focused talks, expert debate and real-world cases

SESSION III – ADVANCED UROTHELIAL CANCER

17:25 – 18:00 | After EV-Pembrolizumab: What Comes Next?

- Sequencing ADCs after EV-P
- FGFR3 inhibition in 2026
- HER2-directed therapies
- Mechanisms of resistance
- Platinum-free strategies
- Triplets and novel combinations
- Real-world treatment algorithms

FINAL PANEL & TAKE-HOME MESSAGES

18:00 – 18:30 | What Will Change Clinical Practice in 2027?

- Will ctDNA become standard of care?
- Are ADCs replacing chemotherapy?
- Will bladder preservation become mainstream?
- Which biomarkers are truly ready for clinical implementation?
- Top practice-changing messages of 2026
- Key unanswered questions

FORMAT | Tumor biology · ctDNA and biomarkers · Therapeutic personalization · ADCs and precision medicine

TRENDING TOPICS | Clinical debates · Practical cases · Dynamic format · Real-world decisions